References in periodicals archive ?
AstraZeneca today announced results from a new analysis of its landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating the risk of all-cause death (ACD), hospitalisation for heart failure (hHF), heart attack (myocardial infarction or MI) and stroke in patients with type-2 diabetes (T2D) receiving treatment with SGLT-2 inhibitors (SGLT-2i), including Farxiga (dapagliflozin) versus other glucose-lowering medicines.
AstraZeneca announced results from a new analysis of its landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating the risk of all-cause death, hospitalization for heart failure, heart attack and stroke in patients with type-2 diabetes receiving treatment with SGLT-2 inhibitors, including Farxiga versus other glucose-lowering medicines.
According to the data, treatment with SGLT-2i medicines -- including Farxiga (dapagliflozin), canagliflozin, empagliflozin -- reduced the rate of hospitalisation for heart failure by 39%, and death from any cause by 51%, compared to other T2D medicines.
TYPES AND NAMES OF DIABETES MEDICATIONS* CLASS BRAND NAMES Biguanides Glucophage, Fortamet GLP-1 receptor agonists Trulicity, Tanzeum, Bydureon, Victoza DPP-IV inhibitors Januvia, Onglyza, Nesina SGLT-2 inhibitors Invokana, Farxiga, Jardiance Sulfonylureas Amaryl, Glucotrol, DiaBeta, Glynase Insulin Tresiba, Toujeo, Afrezza, Levemir, Lantus Combination drugs Janumet, Jentadueto, Kombiglyze, Tradjenta, Kazano, Oseni * This chart provides examples of some, but not all, medications used to treat diabetes.
Invokana, Duetact and Farxiga are the substance of television commercials.
Farxiga (R) [package insert] Princeton NJ; Bristol-Myers Squibb Inc; 01 2014.
7bn (EUR2bn) from AstraZeneca and expects a further milestone consideration of USD600m by mid-February related to the approval in the US of the Farxiga drug, as well as potential regulatory and sales-based milestone payments of up to USD800m and royalty payments based on net sales through 2025.
Farxiga is a once-a-day tablet designed to help diabetes patients eliminate excess sugar via their urine.
Alongside our CVMD medicines Brilinta and Farxiga reaching blockbuster status, we launched our first Respiratory biologic medicine, Fasenra and new cancer medicines, Imfinzi and Calquence.
declined 10% to $376 million, as the company prioritized Farxiga.
SGLT-2 inhibitors, including FARXIGA (dapagliflozin), have demonstrated reductions in HbA1c and have also been shown to reduce weight and blood pressure.
AstraZeneca presented new data at the American Diabetes Associations (ADA) 77th Scientific Sessions underpinning the safety profile of Farxiga (dapagliflozin) with an analysis of data pooled from dapagliflozin clinical trials1, as well as three new cardiovascular (CV) outcomes analyses from the ongoing CVD-REAL study, the first large real-world evidence study of its kind evaluating treatment with SGLT-2 inhibitors (SGLT-2i), including dapagliflozin.